Status:
COMPLETED
Study Comparing Satisfaction of Hospitalized Patients Receiving Invasive Care for Cancer Treatment, With Snoezelen Session Versus Standard Care
Lead Sponsor:
Institut de cancérologie Strasbourg Europe
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a monocentric, comparative, open-label, randomized, crossover study enrolling patients hospitalized in Strasbourg Europe Cancerology Institute, receiving repeated invasive care for cancer trea...
Detailed Description
Patients will followed during two visits for a repeated invasive care. They will be randomized to two groups in a 1:1 ratio. Crossover plan and arms are described as follow: Arm A : Visit 1 with Sno...
Eligibility Criteria
Inclusion
- Patients treated for cancer and hospitalized for invasive care
- Two programmed hospitalization for repeated care
- Patients receiving one of the following invasive care: Huber needle application (transfusion, parenteral nutrition), complex wound dressing, intrathecal chemotherapy, ascites fluid or pleural puncture
- Patients must be ≥ 18 years old
- Performance Status ≤ 3
- Absence of psychiatric disorder impairing follow-up
- Ability to speak, understand, write and read French
- Signed informed consent from the patient
- Affiliation to social security system
Exclusion
- Patients presenting infectious symptoms requiring isolation
- Patients \< 18 years old or patients ≥ 18 years old under supervision
- Patients placed under judicial protection or guardianship
- Women that are pregnant or breast-feeding
Key Trial Info
Start Date :
April 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04783363
Start Date
April 12 2021
End Date
September 18 2023
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de cancérologie Strasbourg Europe
Strasbourg, France, 67033